Company: IMNN
Filing Date: 2025-05-13
Form Type: S-1/A
Source: 0001641172-25-009814
Chunk: 39

Company: Imunon, Inc.
Filing Date: 2025-05-13
Form: S-1/A
Chunk 39
---
 affiliates) may not exercise any portion of the common warrant to the extent that the holder would own more than 4.99% (or, at the election of the holder, 9.99%) of the outstanding Common Stock immediately after exercise, except that upon at least 61 days’ prior notice from the holder to us, the holder may increase or decrease the Beneficial Ownership Limitation to a percentage not to exceed 9.99%. No fractional shares of Common Stock will be issued in connection with the exercise of a common warrant. In lieu of fractional shares, we will round down to the next whole share of Common Stock. The common warrants will expire two and one-half (2.5) years after the Initial Exercise Date.

Cashless Exercise and Alternative Cashless Exercise

If, at the time
a holder exercises its common warrants, a registration statement registering the issuance of the shares of Common Stock underlying the
common warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the
cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect
instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a
formula set forth in the common warrants.

Holders may also effect an “alternative cashless exercise” at any time while the common warrants are outstanding following the Initial Exercise Date. Under the alternative cashless exercise option, a holder of a common warrant has the right to receive an aggregate number of shares equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash rather than a cashless exercise of the common warrant and (ii) 3.0. Accordingly, it is highly unlikely that a holder of the common warrants would wish to pay an exercise price in cash to receive one share of Common Stock when they could instead choose the alternative cashless exercise option and pay no cash to receive three shares of Common Stock. As a result, we will likely not receive, and do not expect to receive, any additional funds upon the exercise of the common warrants.

Stockholder Approval

The exercisability of the common warrants will be available only upon receipt of Stockholder Approval, including such stockholder approval as may be required by the applicable rules and regulations of Nasdaq, including, but not limited to, with respect to (i) such approval as may be required by the applicable rules and